Astellas Pharma’s Bold $5.9B Move: Revolutionizing the Future of Ophthalmic Care
In a monumental deal, Japan-based pharmaceutical giant Astellas Pharma announced its acquisition of Iveric Bio for $5.9 billion, marking a significant step in its continued expansion into the global ophthalmic drug market. The acquisition solidifies Astellas Pharma’s commitment to developing innovative treatments for eye-related disorders and showcases the company’s strategic approach in bolstering its pipeline … Read more